Business
CARDIO inCode-Score presentation
CARDIO inCode-Score presentation.
About this update from Genincode Plc
[{"type":"text","content":"\n\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nCARDIO inCode-Score® presentation on polygenic risk of Coronary Heart Disease\nat 2024 European Society of Cardiology (ESC) Annual Congress, London\n \nOxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces the presentation by Kaiser Permanente on the interplay between family history and polygenic risk on the incidence of coronary heart disease (\"CHD\") which will take place at the 2024 Annual Congress of the European Society of Cardiology (\"ESC\") in London from 30 August to 2 September 2024.\n \nFollowing the March 2024 milestone publication in the American Journal of Preventive Cardiology1, this latest study shows CARDIO inCode-Score® PRS and family history in first degree relatives independently contribute to the risk of incident CHD, with a 42% increase in risk in the presence of a positive family history and a 64% increase where the patient has a high polygenic risk score (\"PRS\"). Importantly, the study showed the joint effect of positive family history and a high polygenic risk increased the hazard or incidence of CHD by 2.3 times. Thus, relying solely on self reported (patient) family history is insufficient to fully characterise the genetic contribution to CHD and PRS is recommended.\n \nThe Kaiser Permanente Division of Research study investigated more than 63,000 adult individuals with no history of CHD who are part of the Kaiser Permanente Northern California Genetic Epidemiology Resource in Adult Health and Aging (\"GERA\") multi-ethnic cohort. The GERA cohort followed the membership over an average of 14 years, using CARDIO inCode-Score® to assess the polygenic risk of CHD and future incidence of risk of CHD.\n \nIndividuals with a high polygenic risk of CHD should be prioritised for lifestyle advice and where appropriate therapeutic intervention as those at the highest polygenic risk will benefit most from earlier and/or more intensified treatment, especially where they have family history. Previous data on CARDIO inCode-Score® presented at last year's ESC showed that where individuals have a high polygenic risk, a favourable lifestyle is associated with a 52% lower rate of CHD compared with an unfavourable lifestyle. The latest study contin...